The NSBCC administrative Core is described. The NSBCC is Directed by Jim Heath and co-Directed by Mike Phelps &Leroy Hood. Heath bears overall responsibility for the center, and specific responsibility for the technology development components. Dr. Hood bears specific responsibility for oversight of the biology (and systems biology) project components, and Dr. Phelps oversees the clinical translation of NSBCC projects. Each of the NSBCC leaders has extensive expertise in technology development, clinical translation, and technology commercialization. The NSBCC Leaders are guided by an Internal Review Council comprised of the Project Principal Investigators, and by an External Advisory Board. Descriptions of that guidance are provided. Rationale for how the scientific and personnel composition of the individual projects provide for a culture in which the sum of the components is greater than the parts is given - including a proven vision for accelerating the process of technology innovation to clinical demonstration. Significant partnerships with NCI funded programs, including the Jonsson Comprehensive Cancer Center, are described. Leverage from foundation funded programs and institutes, such as the Broad Institute for Regenerative Medicine, are discussed. Additional funding from foundation and other resources provides significant leverage for the NSBCC projects, and significantly accelerates our pathway into the clinic. Additional partnerships with for-profit companies (Sofie Biosciences, Integrated Diagnostics, and Momentum Biosciences) are described. Examples of how these partnerships are already leading to the commercial development of NSBCC technologies (from existing CCNE funding) are provided.
The NSBCC adminstration Core is designed to enable the success of our Projects, and to maximize the interaction of the NSBCC with the local oncology and cancer biology community. Internal and external oversight boards, meeting on a regular basis, provide guidance for steering NSBCC scientific programs and evaluating trans-Alliance and other opportunities as they arise.
|Thai, Minh; Graham, Nicholas A; Braas, Daniel et al. (2014) Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab 19:694-701|
|Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25:364-73|
|Zhao, Jimmy L; Ma, Chao; O'Connell, Ryan M et al. (2014) Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell 14:445-59|
|Wong, Deborah J L; Rao, Amol; Avramis, Earl et al. (2014) Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res 2:459-68|
|Robert, Lidia; Tsoi, Jennifer; Wang, Xiaoyan et al. (2014) CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 20:2424-32|
|Nathanson, David A; Gini, Beatrice; Mottahedeh, Jack et al. (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72-6|
|Chodon, Thinle; Comin-Anduix, Begoña; Chmielowski, Bartosz et al. (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457-65|
|Ribas, Antoni; Tumeh, Paul C (2014) The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 20:4982-4|
|Gini, Beatrice; Mischel, Paul S (2014) Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discov 4:876-8|
|Akhavan, David; Pourzia, Alexandra L; Nourian, Alex A et al. (2013) De-repression of PDGFR* transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 3:534-47|
Showing the most recent 10 out of 22 publications